Sewoon Bio, a South Korean regenerative medicine company, has signed a supply agreement with Chinese medical aesthetics firm UPS BIO to launch a new hyaluronic acid (HA) filler brand 'Eloyan' in China. This multi-brand strategy aims to capture a broader market share, targeting approximately 30 billion KRW in brand sales over five years through local distribution networks.
Partnership details
Sewoon Bio (CEO Yoo Hyun-seung) recently signed a cooperation agreement with ZheJiang Ups Biotechnology Co., Ltd. (UPS BIO) for the supply of HA filler products and the launch of the new brand 'Eloyan'. This marks the company's first multi-brand initiative in China, following its existing HA filler brand 'GISELLELIGNE'.
Market strategy
China's medical aesthetics market features diverse brand preferences and consumer characteristics across regions and channels, making multi-brand segmentation a common approach. Leveraging experience from GISELLELIGNE's operations and product competitiveness, Sewoon Bio will combine UPS BIO's local distribution and marketing capabilities to target a wider customer base and distribution channels.
Partner profile
UPS BIO specializes in nurturing and distributing global aesthetic brands in China's medical aesthetics market. It possesses a network of medical aesthetics hospitals and KOL-based marketing capabilities, with experience in bringing German and Korean HA fillers, PN skin boosters, and other global medical aesthetic products into the Chinese market.
Product and regulatory context
The HA filler products covered by this agreement received NMPA approval in 2019 and have been supplied under the GISELLELIGNE brand. Sewoon Bio plans to launch Eloyan based on this experience, building a brand portfolio optimized for regional and channel-specific characteristics to strengthen its market presence.
What buyers should watch
Distributors and clinic buyers should note the 5-year contract term and the 30 billion KRW sales target. The partnership signals Sewoon Bio's commitment to expanding its HA filler portfolio in China, potentially offering new sourcing opportunities for multi-brand strategies. The existing NMPA approval for the product base may streamline regulatory compliance for new brand introductions.
Source: Read the original report | Published: June 02, 2026